FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892009123> ?p ?o ?g. }

• W2892009123 abstract "Glioblastoma is the most common and lethal intracranial tumor type, characterized by high angiogenic and infiltrative capacities. To provide a novel insight into therapeutic strategies against glioblastoma, the cytotoxicity of arenobufagin and hellebrigenin was investigated in the human glioblastoma cell line, U-87. Similar dose-dependent cytotoxicity was observed in the cells, whereas no detectable toxicity was confirmed in mouse primary astrocytes. Treatment with each drug downregulated the expression levels of Cdc25C, Cyclin B1 and survivin, which occurred in parallel with G2/M phase arrest. Necrotic-like cell death was only observed in the cells treated with a relatively high concentration (>100 ng/ml). These results indicate that the two drugs exhibited distinct cytotoxicity against cancerous glial cells with high potency and selectivity, suggesting that growth inhibition associated with G2/M phase arrest and/or necrosis were attributed to their toxicities. Activation of the p38 mitogen activated protein kinase (MAPK) signaling pathway was also observed in treated cells. Notably, a specific inhibitor of p38 MAPK, SB203580, itself caused a significant decrease in cell viability, and further enhanced the cytotoxicity of the two drugs, suggesting an important pro-survival role for p38 MAPK. Given that p38 MAPK serves an essential role in promoting glioblastoma cell survival, developing a novel combination regimen of arenobufagin/hellebrigenin plus a p38 MAPK inhibitor may improve the efficacy of the two drugs, and may provide more therapeutic benefits to patients with glioblastoma. The qualitative assessment demonstrated the existence of arenobufagin in the cerebrospinal fluid of arenobufagin-treated rats, supporting its clinical application." @default.
• W2892009123 created "2018-09-27" @default.
• W2892009123 creator A5011390933 @default.
• W2892009123 creator A5030521144 @default.
• W2892009123 creator A5046985252 @default.
• W2892009123 creator A5049806492 @default.
• W2892009123 creator A5053407094 @default.
• W2892009123 creator A5069786005 @default.
• W2892009123 creator A5076824143 @default.
• W2892009123 creator A5085860172 @default.
• W2892009123 date "2018-09-20" @default.
• W2892009123 modified "2023-10-13" @default.
• W2892009123 title "Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87" @default.
• W2892009123 cites W1505329258 @default.
• W2892009123 cites W1969299292 @default.
• W2892009123 cites W1971437637 @default.
• W2892009123 cites W1972713981 @default.
• W2892009123 cites W1973485926 @default.
• W2892009123 cites W1979235615 @default.
• W2892009123 cites W1980224606 @default.
• W2892009123 cites W2001198728 @default.
• W2892009123 cites W2002196794 @default.
• W2892009123 cites W2004708987 @default.
• W2892009123 cites W2006759899 @default.
• W2892009123 cites W2007345690 @default.
• W2892009123 cites W2010542563 @default.
• W2892009123 cites W2012960469 @default.
• W2892009123 cites W2014994637 @default.
• W2892009123 cites W2016487885 @default.
• W2892009123 cites W2018527946 @default.
• W2892009123 cites W2028706407 @default.
• W2892009123 cites W2036044314 @default.
• W2892009123 cites W2036790367 @default.
• W2892009123 cites W2043323745 @default.
• W2892009123 cites W2044345256 @default.
• W2892009123 cites W2048738987 @default.
• W2892009123 cites W2050599698 @default.
• W2892009123 cites W2055060001 @default.
• W2892009123 cites W2058294429 @default.
• W2892009123 cites W2061842603 @default.
• W2892009123 cites W2066670388 @default.
• W2892009123 cites W2075582004 @default.
• W2892009123 cites W2087861588 @default.
• W2892009123 cites W2088925558 @default.
• W2892009123 cites W2094709780 @default.
• W2892009123 cites W2096287682 @default.
• W2892009123 cites W2097917250 @default.
• W2892009123 cites W2107495112 @default.
• W2892009123 cites W2111869518 @default.
• W2892009123 cites W2112932851 @default.
• W2892009123 cites W2117115065 @default.
• W2892009123 cites W2127687001 @default.
• W2892009123 cites W2136897326 @default.
• W2892009123 cites W2139008103 @default.
• W2892009123 cites W2151335185 @default.
• W2892009123 cites W2196202684 @default.
• W2892009123 cites W2275101974 @default.
• W2892009123 cites W2411649863 @default.
• W2892009123 cites W2460426198 @default.
• W2892009123 cites W2492306183 @default.
• W2892009123 cites W2509121458 @default.
• W2892009123 cites W2596065061 @default.
• W2892009123 cites W2598710356 @default.
• W2892009123 cites W2602832336 @default.
• W2892009123 cites W2644370144 @default.
• W2892009123 cites W4230908322 @default.
• W2892009123 cites W4362029913 @default.
• W2892009123 doi "https://doi.org/10.3892/ijo.2018.4567" @default.
• W2892009123 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6203163" @default.
• W2892009123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30272276" @default.
• W2892009123 hasPublicationYear "2018" @default.
• W2892009123 type Work @default.
• W2892009123 sameAs 2892009123 @default.
• W2892009123 citedByCount "11" @default.
• W2892009123 countsByYear W28920091232019 @default.
• W2892009123 countsByYear W28920091232020 @default.
• W2892009123 countsByYear W28920091232021 @default.
• W2892009123 countsByYear W28920091232022 @default.
• W2892009123 countsByYear W28920091232023 @default.
• W2892009123 crossrefType "journal-article" @default.
• W2892009123 hasAuthorship W2892009123A5011390933 @default.
• W2892009123 hasAuthorship W2892009123A5030521144 @default.
• W2892009123 hasAuthorship W2892009123A5046985252 @default.
• W2892009123 hasAuthorship W2892009123A5049806492 @default.
• W2892009123 hasAuthorship W2892009123A5053407094 @default.
• W2892009123 hasAuthorship W2892009123A5069786005 @default.
• W2892009123 hasAuthorship W2892009123A5076824143 @default.
• W2892009123 hasAuthorship W2892009123A5085860172 @default.
• W2892009123 hasBestOaLocation W28920091231 @default.
• W2892009123 hasConcept C109316439 @default.
• W2892009123 hasConcept C1491633281 @default.
• W2892009123 hasConcept C184235292 @default.
• W2892009123 hasConcept C202751555 @default.
• W2892009123 hasConcept C29537977 @default.
• W2892009123 hasConcept C502942594 @default.
• W2892009123 hasConcept C51551487 @default.
• W2892009123 hasConcept C54355233 @default.
• W2892009123 hasConcept C55493867 @default.
• W2892009123 hasConcept C57074206 @default.
• W2892009123 hasConcept C62112901 @default.

• next